IDEXX LABORATORIES INC /DE Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $332.34M, a 1.17% increase year-over-year.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $371.39M, a 10.58% decline year-over-year.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $242.08M, a 2.67% decline year-over-year.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $241.65M, a 7.32% increase year-over-year.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for fiscal 2025 was $1.23B, a 42.83% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for fiscal 2024 was $859.43M, a 940.31% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for fiscal 2023 was $82.61M, a 89.94% decline from fiscal 2022.
- IDEXX LABORATORIES INC /DE treasury stock, value, acquired, cost method for fiscal 2022 was $821.55M, a 6.54% increase from fiscal 2021.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $332.34M 10-Q · filed 2026-08-04 | $1.19B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $371.39M 10-Q · filed 2026-05-05 | $1.18B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $242.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.23B 10-K · filed 2026-02-20 |
| 2025-09-30 | $241.65M 10-Q · filed 2025-11-03 | $1.23B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $328.50M 10-Q · filed 2026-08-04 | $1.22B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $415.34M 10-Q · filed 2026-05-05 | $1.10B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $248.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $859.43M 10-K · filed 2026-02-20 |
| 2024-09-30 | $225.16M 10-Q · filed 2025-11-03 | $648.34M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $208.25M 10-Q · filed 2025-08-04 | $458.48M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $177.29M 10-Q · filed 2025-05-01 | $250.31M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $37.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $82.61M 10-K · filed 2026-02-20 |
| 2023-09-30 | $35.30M 10-Q · filed 2024-10-31 | $113.31M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $79.00K 10-Q · filed 2024-08-06 | $244.60M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $9.60M 10-Q · filed 2024-05-01 | $558.02M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $68.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $821.55M 10-K · filed 2025-02-21 |
| 2022-09-30 | $166.59M 10-Q · filed 2023-11-01 | $997.88M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $313.51M 10-Q · filed 2023-08-01 | $1.02B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $273.12M 10-Q · filed 2023-05-02 | $890.03M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $244.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $771.11M 10-K · filed 2024-02-22 |
| 2021-09-30 | $183.83M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $188.41M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $154.20M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $200.23M 10-K · filed 2023-02-16 | |
| 2020-09-30 | $360.00K 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $187.77M 10-Q · filed 2021-11-02 | |
| 2019-12-31 | $311.89M 10-K · filed 2022-02-16 | |
| 2019-09-30 | $91.32M 10-Q · filed 2020-10-29 | $276.55M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $20.34M 10-Q · filed 2020-10-29 | $258.73M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | $61.13M 10-Q · filed 2020-10-29 | $344.22M derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $103.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $378.07M 10-K · filed 2021-02-12 |
| 2018-09-30 | $73.50M 10-Q · filed 2019-10-31 | $328.85M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-06-30 | $105.83M 10-Q · filed 2019-10-31 | $306.12M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-03-31 | $94.28M 10-Q · filed 2019-10-31 | $314.61M derived: sum of 4 quarters · filed 2020-02-14 |
| 2017-12-31 | $55.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $278.37M 10-K · filed 2020-02-14 |
| 2017-09-30 | $50.78M 10-Q · filed 2018-11-01 | $448.41M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | $114.32M 10-Q · filed 2018-08-01 | $413.10M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | $58.05M 10-Q · filed 2018-05-04 | $322.25M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | $225.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $317.44M 10-K · filed 2019-02-15 |
| 2016-09-30 | $15.48M 10-Q · filed 2017-10-31 | $185.79M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $23.46M 10-Q · filed 2017-08-01 | $256.43M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $53.24M 10-Q · filed 2017-04-28 | $326.62M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $93.61M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $411.89M 10-K · filed 2018-02-16 |
| 2015-09-30 | $86.11M 10-Q · filed 2016-11-01 | $473.28M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $93.66M 10-Q · filed 2016-08-02 | $659.51M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $138.51M 10-Q · filed 2016-04-29 | $692.20M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $155.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $623.97M 10-K · filed 2017-02-17 |
| 2014-09-30 | $272.34M 10-Q · filed 2015-10-28 | $558.37M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-06-30 | $126.35M 10-Q · filed 2015-07-30 | $362.60M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-03-31 | $70.28M 10-Q · filed 2015-04-28 | $378.81M derived: sum of 4 quarters · filed 2016-02-17 |
| 2013-12-31 | $89.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-17 | $372.31M 10-K · filed 2016-02-17 |
| 2013-09-30 | $76.58M 10-Q · filed 2014-10-24 | $324.03M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $142.56M 10-Q · filed 2014-07-25 | $283.60M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $63.78M 10-Q · filed 2014-04-25 | $168.42M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $132.27M 10-K · filed 2015-02-17 |
| 2012-09-30 | $36.15M 10-Q · filed 2013-10-22 | $180.64M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-06-30 | $27.38M 10-Q · filed 2013-07-23 | $212.09M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-03-31 | $27.63M 10-Q · filed 2013-04-23 | $243.19M derived: sum of 4 quarters · filed 2014-02-18 |
| 2011-12-31 | $89.49M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-18 | $255.50M 10-K · filed 2014-02-18 |
| 2011-09-30 | $67.60M 10-Q · filed 2012-10-19 | $191.95M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $58.48M 10-Q · filed 2012-07-20 | $157.78M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $39.94M 10-Q · filed 2012-04-20 | $125.30M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $143.09M 10-K · filed 2013-02-19 |
| 2010-09-30 | $33.43M 10-Q · filed 2011-10-21 | |
| 2010-06-30 | $26.00M 10-Q · filed 2011-07-22 | |
| 2009-12-31 | $83.10M 10-K · filed 2012-02-17 | |
| 2008-12-31 | $133.72M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |